Rep. Bruce Westerman Sells Roche Holding AG (OTCMKTS:RHHBY) Shares

Representative Bruce Westerman (R-Arkansas) recently sold shares of Roche Holding AG (OTCMKTS:RHHBY). In a filing disclosed on May 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Roche stock on April 21st. The trade occurred in the Representative’s “FISHER IRA” account.

Representative Bruce Westerman also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of UniCredit (OTCMKTS:UNCRY) on 4/21/2025.
• Sold $1,001 – $15,000 in shares of CSX (NASDAQ:CSX) on 4/21/2025.
• Sold $1,001 – $15,000 in shares of Siemens Aktiengesellschaft (OTCMKTS:SIEGY) on 4/21/2025.
• Sold $1,001 – $15,000 in shares of GSK (NYSE:GSK) on 4/21/2025.
• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 4/21/2025.
• Sold $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 4/21/2025.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 4/21/2025.
• Sold $1,001 – $15,000 in shares of Eli Lilly and Company (NYSE:LLY) on 4/21/2025.
• Sold $15,001 – $50,000 in shares of NVIDIA (NASDAQ:NVDA) on 4/21/2025.
• Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 4/21/2025.

Roche Trading Down 2.6%

RHHBY opened at $37.34 on Thursday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.97 and a current ratio of 1.26. Roche Holding AG has a 52 week low of $31.19 and a 52 week high of $44.31. The business has a 50 day moving average of $40.19 and a 200-day moving average of $38.62.

Institutional Trading of Roche

A number of institutional investors and hedge funds have recently modified their holdings of the business. Corient IA LLC bought a new position in shares of Roche during the first quarter valued at $616,000. FCA Corp TX purchased a new position in Roche in the 1st quarter worth about $494,000. Atlas Capital Advisors Inc. bought a new position in Roche during the 1st quarter valued at about $140,000. Everett Harris & Co. CA purchased a new stake in shares of Roche during the 1st quarter valued at about $445,000. Finally, Accent Capital Management LLC bought a new stake in shares of Roche in the first quarter worth approximately $35,000.

Analyst Ratings Changes

Several equities analysts have commented on RHHBY shares. Hsbc Global Res lowered Roche from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 28th. Morgan Stanley initiated coverage on Roche in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. UBS Group raised Roche from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Sanford C. Bernstein raised shares of Roche to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, HSBC lowered shares of Roche from a “buy” rating to a “hold” rating in a research note on Monday, April 28th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Roche has an average rating of “Hold”.

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas’ 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.

Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas’ 4th Congressional District. He declared candidacy for the 2026 election.

Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.